A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Trial Profile

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 10 Jul 2017 Status changed from active, no longer recruiting to discontinued as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation
    • 03 Feb 2017 This trial has been completed in Spain (end date: 24 Jan 2017).
    • 24 May 2016 The trial was prematurely ended in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top